HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neuroprotective effect of ligustilide against ischaemia-reperfusion injury via up-regulation of erythropoietin and down-regulation of RTP801.

AbstractBACKGROUND AND PURPOSE:
Ligustilide, the main lipophilic component of Danggui, has been reported to protect the brain against ischaemic injury. However, the mechanisms are unknown. Here, we investigated the roles of erythropoietin (EPO) and the stress-induced protein RTP801 in neuroprotection provided by ligustilide against ischaemia-reperfusion (I/R) damage to the brain.
EXPERIMENTAL APPROACH:
The efficacy of ligustilide against I/R damage was assessed by neurological deficit, infarct volume and cell viability, using the middle cerebral artery occlusion model in rats in vivo and rat cultured neurons in vitro. EPO and RTP801 were analysed by Western blot. Over-expression of RTP801 was achieved by transfection of an expression plasmid.
KEY RESULTS:
Ligustilide decreased the neurological deficit score, infarct volume and RTP801 expression and increased EPO transcription in I/R rats, and increased cell viability and EPO and decreased LDH release and RTP801 in I/R neurons. Also, ligustilide increased ERK phosphorylation (p-ERK). The positive effects of ligustilide on p-ERK, cell viability and EPO were blocked by PD98059, but not LY294002 and SB203580. In addition, transfection of SH-SY5Y cells with RTP801 plasmid increased RTP801 and LDH release, while ligustilide inhibited the effects of transfection on RTP801 expression and also increased cell viability.
CONCLUSION AND IMPLICATIONS:
Ligustilide exerts neuroprotective effects against I/R injury by promoting EPO transcription via an ERK signalling pathway and inhibiting RTP801 expression, This compound could be developed into a therapeutic agent to prevent and treat ischaemic disorders.
AuthorsXiao-mei Wu, Zhong-ming Qian, Li Zhu, Fang Du, Wing-ho Yung, Qi Gong, Ya Ke
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 164 Issue 2 Pg. 332-43 (Sep 2011) ISSN: 1476-5381 [Electronic] England
PMID21410687 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.
Chemical References
  • Chromones
  • Ddit4 protein, rat
  • Flavonoids
  • Imidazoles
  • Morpholines
  • Pyridines
  • Repressor Proteins
  • Transcription Factors
  • Erythropoietin
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • ligustilide
  • L-Lactate Dehydrogenase
  • Glucose
  • 4-Butyrolactone
  • SB 203580
  • Oxygen
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
Topics
  • 4-Butyrolactone (analogs & derivatives, pharmacology)
  • Animals
  • Cell Line
  • Chromones (pharmacology)
  • Erythropoietin (genetics, metabolism)
  • Flavonoids (pharmacology)
  • Gene Expression Regulation (drug effects)
  • Glucose (metabolism)
  • Imidazoles (pharmacology)
  • L-Lactate Dehydrogenase
  • Male
  • Morpholines (pharmacology)
  • Neurons (drug effects)
  • Oxygen (metabolism)
  • Plasmids
  • Pyridines (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Reperfusion Injury (drug therapy)
  • Repressor Proteins (genetics, metabolism)
  • Transcription Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: